Stockscreener 앱 받기
496.07
2.49%
12.04
전일 마감가:
$484.03
열려 있는:
$487.11
하루 거래량:
986.81K
Relative Volume:
0.67
시가총액:
$125.91B
수익:
$12.34B
순이익/손실:
$4.34B
주가수익비율:
29.41
EPS:
16.8685
순현금흐름:
$3.71B
1주 성능:
+3.98%
1개월 성능:
-5.01%
6개월 성능:
+3.80%
1년 성능:
+32.06%
1일 변동 폭
$482.10
$497.39
1주일 범위
$465.51
$497.39
52주 변동 폭
$362.50
$533.67
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect? - TradingView
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
OMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vertex Pharmaceuticals Incorporated $VRTX Position Reduced by Cetera Investment Advisers - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bank of Nova Scotia - MarketBeat
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Renaissance Technologies LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc. - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 45,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals Inc (VRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:478.960|Chg%:+1.600 - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:473.090| - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:477.360|Chg%:+4.270 - TradingKey
Caxton Associates LLP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gibbs Wealth Management Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record territory as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
CI Investments Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Has $136.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vertex Pharmaceuticals (VRTX) EVP Amit Sachdev receives 8,251-share equity grant - Stock Titan
Vertex stock consolidates after strong Q1 2026 revenue growth - Ad-hoc-news.de
3 Healthcare Stocks with Competitive Advantages - Yahoo! Finance Canada
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower - Yahoo Finance
Aureus Asset Management LLC Has $3.75 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex was sole bidder in high-premium Crinetics acquisition - BioPharma Dive
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex was only bidder for Crinetics in year’s second-highest M&A premium - Endpoints News
Madison Asset Management LLC Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Takes $11.67 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Former Vertex chief Jeff Leiden’s latest venture: a ‘smart’ toilet seat - The Boston Globe
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation - ChartMill
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by KBC Group NV - MarketBeat
Meeder Asset Management Inc. Buys 2,799 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19 - marketscreener.com
Dimensional Fund Advisors LP Buys 43,682 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Sells 8,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
버텍스 파마슈티컬 주식 (VRTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
1.59%
1.17%
자본화:
|
볼륨(24시간):